Pituitary tumors are benign neoplasms originating from anterior pituitary cells, accounting for 10%–15% of all intracranial tumors. Approximately 60%–70% of patients develop varying degrees of endocrine dysfunction. As the central regulatory hub of the human endocrine system, the pituitary gland disrupts systematic hormonal homeostasis once affected by tumors. Tumor-induced hormone hypersecretion or mass compression of normal pituitary tissue triggers diverse endocrine abnormalities, severely impairing patients’ quality of life and reproductive function.

According to data published in the Chinese Journal of Endocrinology and Metabolism (2025), the annual incidence of pituitary tumors in China is approximately 7.5 per 100,000 population, with a slight female predominance and the highest prevalence among young and middle-aged individuals aged 20–50 years.

1. Medical Correlation Between Pituitary Tumors and Endocrine Disorders

1.1 Endocrine Regulatory Function of the Pituitary Gland

Located within the sella turcica, the pituitary gland consists of anterior and posterior lobes. The anterior lobe synthesizes and secretes core hormones, including prolactin (PRL), growth hormone (GH), adrenocorticotropic hormone (ACTH), and thyroid-stimulating hormone (TSH), which govern the functional activities of target organs such as the thyroid, adrenal glands, and gonads. Pituitary tumorigenesis disrupts this precise regulatory network, resulting in either excessive or insufficient hormonal secretion.

1.2 Clinical Impacts of Tumor-Related Endocrine Disorders

Endocrine disturbances secondary to pituitary tumors disrupt systemic metabolism and reproductive function, and significantly increase the risk of cardiovascular diseases and osteoporosis. A 2024 study from Peking Union Medical College Hospital demonstrated that untreated patients with pituitary tumor-related endocrine disorders have a 2–3-fold higher incidence of cardiovascular events and a 40% increased risk of osteoporosis compared with the general population.

2. Pathological Mechanisms: Hormonal Hypersecretion and Mass Compression

2.1 Hormonal Over-Secretion by Functional Pituitary Tumors

2.1.1 Prolactinomas (PRL-Secreting Tumors)

Accounting for 40%–50% of all pituitary tumors, prolactinomas are the most common functional pituitary neoplasms. Excessive prolactin secretion disrupts neuroendocrine homeostasis via two core mechanisms: inhibiting hypothalamic gonadotropin-releasing hormone (GnRH) secretion to reduce luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, and directly suppressing ovarian estrogen synthesis and ovulation. A 2024 study from Shanghai Jiao Tong University School of Medicine confirmed that over 90% of patients with serum PRL levels exceeding 200 ng/mL present with overt endocrine symptoms.

2.1.2 Growth Hormone Tumors (GH-Secreting Tumors)

GH tumors constitute 10%–15% of pituitary tumors. Persistent GH hypersecretion induces severe metabolic and somatic abnormalities. Growth hormone antagonizes insulin activity, causing impaired glucose tolerance or clinical diabetes in 60% of patients. In adults, excessive GH leads to acromegaly characterized by soft tissue and skeletal overgrowth, while pediatric patients develop gigantism. Concurrent gonadal suppression commonly results in hypogonadism and sexual dysfunction.

2.1.3 ACTH-Secreting Tumors (Cushing’s Disease)

ACTH tumors account for 5%–10% of pituitary tumors. Excessive ACTH stimulates adrenal cortical hyperplasia and overproduction of glucocorticoids, leading to Cushing’s disease. Glucocorticoid excess accelerates hepatic glycogenolysis and inhibits peripheral glucose utilization, causing hyperglycemia in 80% of patients. It also induces disordered fat metabolism, presenting typical central obesity and buffalo hump, and suppresses the hypothalamic-pituitary-gonadal axis, resulting in menstrual irregularities in females and erectile dysfunction in males.

2.2 Mass Compression Effects of Non-Functional Pituitary Tumors

2.2.1 Pituitary Stalk Compression

Tumor compression of the pituitary stalk interrupts hypothalamic dopaminergic inhibition on prolactin secretion, causing mild hyperprolactinemia (usually < 100 ng/mL). Approximately 30% of affected patients develop galactorrhea and menstrual irregularities.

2.2.2 Atrophy of Normal Pituitary Parenchyma

Space-occupying tumors compress and atrophy functional pituitary tissue, leading to multiple hormonal deficiencies. Gonadotropin insufficiency causes decreased libido, amenorrhea, and infertility. TSH deficiency results in hypothyroidism manifesting as fatigue, cold intolerance, and hypometabolism. ACTH insufficiency induces adrenocortical hypofunction with nausea, vomiting, and orthostatic hypotension.

2.3 Gender and Age-Related Differences in Clinical Manifestations

Female patients have a significantly higher prevalence of prolactinomas (male-to-female ratio = 1:3), with predominant symptoms of menstrual disturbance and galactorrhea.Male patients are more prone to non-functional pituitary tumors, with atypical early symptoms and sexual dysfunction as the initial presentation. Pediatric and adolescent patients with GH tumors develop gigantism and delayed puberty due to disrupted gonadal development.

3. Typical Symptoms of Pituitary Tumor-Related Endocrine Disorders

3.1 Clinical Manifestations in Female Patients

3.1.1 Menstrual Abnormalities

70%–80% of females with prolactinomas present with oligomenorrhea, hypomenorrhea, or secondary amenorrhea due to PRL-mediated ovulation inhibition. 30%–40% of patients with non-functional tumors develop amenorrhea secondary to gonadotropin deficiency caused by pituitary stalk compression or parenchymal atrophy.

3.1.2 Galactorrhea and Infertility

Non-puerperal galactorrhea (white or pale milky discharge) occurs in 50% of hyperprolactinemic patients. Disrupted ovulation and luteal function lead to infertility. Data from Beijing Obstetrics and Gynecology Hospital (2024) indicates that pituitary tumor-related infertility accounts for 10%–15% of female infertility etiologies.

3.1.3 Other Associated Symptoms

20% of female Cushing’s disease patients develop hirsutism and acne due to elevated androgen levels induced by excess glucocorticoids. A small proportion of patients with GH tumors present with mild acromegalic features and diabetic symptoms including polydipsia and polyuria secondary to insulin resistance.

3.2 Clinical Manifestations in Male Patients

3.2.1 Sexual Dysfunction

60%–70% of males with prolactinomas suffer from decreased libido and erectile dysfunction, with aggravated symptoms when serum PRL exceeds 100 ng/mL. Patients with non-functional tumors develop hypogonadism and regressed secondary sexual characteristics due to reduced testosterone synthesis from gonadotropin deficiency.

3.2.2 Impaired Fertility

Decreased sperm quantity and quality significantly reduce fertility potential, with 40% of male pituitary tumor patients diagnosed with infertility. GH excess further impairs spermatogenesis and sperm motility.

3.2.3 Systemic Manifestations

Male Cushing’s disease patients present with central obesity, refractory hypertension, and concurrent sexual hypofunction. Acromegalic patients develop enlarged extremities and coarsened facial features, with 30% complicated by obstructive sleep apnea syndrome.

3.3 Characteristic Manifestations of Special Pituitary Tumor Subtypes

3.3.1 Classic Features of Cushing’s Disease

Central obesity occurs in 90% of patients, characterized by abdominal and cervical fat deposition with relatively slender extremities. Glucocorticoid-induced collagen degradation causes thin skin, purple abdominal/thigh striae, and recurrent acne. Sodium and water retention plus increased vascular sensitivity lead to hypertension in 80% of cases.

3.3.2 Progressive Manifestations of Acromegaly

Progressive skeletal and soft tissue remodeling causes supraorbital ridge prominence, mandibular prognathism, thickened nasal and lip tissues, with obvious phenotypic changes typically developing after more than 5 years of disease progression. Macroglossia and thickened vocal cords result in hoarseness, while cardiomegaly may progress to heart failure. Up to 60% of patients develop diabetes or impaired glucose tolerance due to GH-induced insulin antagonism.

3.4 Symptoms in Children and Adolescents

GH tumors cause pathological gigantism with excessive growth velocity, ceasing after epiphyseal closure. Gonadotropin deficiency delays puberty, with absence of secondary sexual characteristics in girls aged over 13 years and boys aged over 14 years. TSH insufficiency reduces basal metabolic rate, leading to persistent cold intolerance, fatigue, and growth retardation.

4. Diagnostic Workup for Pituitary Tumor-Related Endocrine Disorders

4.1 Core Laboratory Assessments

4.1.1 Basal Hormone Profiling

Fasting serum PRL > 25 ng/mL confirms hyperprolactinemia, while levels > 200 ng/mL are highly suggestive of prolactinoma. Random GH > 5 μg/L requires further oral glucose tolerance testing (OGTT), with normal suppressed GH nadir < 1 μg/L. Elevated ACTH (> 40 pg/mL) accompanied by loss of cortisol diurnal rhythm supports a diagnosis of Cushing’s disease.

Routine tests also include TSH, free thyroid hormones, LH, FSH, estradiol, progesterone, and testosterone to comprehensively evaluate hypothalamic-pituitary-target gland axis function.

4.1.2 Dynamic Functional Tests

OGTT is the gold standard for GH tumor diagnosis; failure to suppress GH below 1 μg/L after 75g oral glucose administration confirms autonomous GH hypersecretion. Low-dose dexamethasone suppression test excludes Cushing’s syndrome, while high-dose testing differentiates pituitary-dependent from adrenal-dependent etiology.

4.2 Imaging Localization

Contrast-enhanced pituitary MRI is the first-line imaging modality. 3.0T MRI detects microadenomas as small as 3 mm. Prolactinomas typically present as unilateral intrasellar low-enhancing lesions, classified as microadenomas (< 1 cm) or macroadenomas (> 1 cm). Non-functional tumors are mostly large adenomas causing pituitary stalk and optic chiasm compression with characteristic T1 and T2 signal alterations.

CT is limited in microadenoma detection but effectively evaluates sellar bony erosion. PET-CT is reserved for atypical cases to differentiate tumor grading and distant metastasis.

4.3 Differential Diagnosis

Pituitary disorders are distinguished from primary target gland diseases, empty sella syndrome, and hypothalamic tumors via combined hormonal profiling and imaging features. Primary hypothyroidism presents with elevated TSH and normal pituitary imaging, while pituitary hypothyroidism shows decreased TSH with visible pituitary lesions. Empty sella syndrome demonstrates flattened pituitary tissue on MRI with mostly normal hormonal levels.

5. Standardized Treatment Strategies

5.1 Management of Prolactinomas

Medical therapy is prioritized. Dopamine agonists (bromocriptine 2.5–10 mg/d or cabergoline 0.5–2 mg/week) normalize PRL levels in 80%–90% of patients, restore menstrual cycles, and achieve 50%–60% tumor volume reduction. Medication is initiated at low doses with gradual titration to minimize gastrointestinal adverse reactions.

Surgical indications include drug resistance (persistent hyperprolactinemia or tumor progression after 3-month standardized therapy) and giant adenomas (> 3 cm) with visual pathway compression, with transsphenoidal resection achieving 60%–70% gross total resection rates.

Stereotactic radiotherapy is indicated for residual or recurrent tumors, with long-term disease control rates of 60%–70% but delayed efficacy and potential hypopituitarism risks.

5.2 Comprehensive Treatment for GH Tumors

Transsphenoidal surgery is the first-line treatment, with gross total resection rates of 80%–90% for microadenomas and 60%–70% for macroadenomas. Postoperative GH < 2.5 μg/L and normalized IGF-1 indicate favorable prognosis.

Somatostatin analogs (octreotide, lanreotide) serve as adjuvant medical therapy to suppress GH secretion, achieving biochemical remission in 60%–70% of patients. Radiotherapy is reserved for postoperative residual disease, with 5-year control rates of 50%–60% and high risks of secondary hypopituitarism.

5.3 Therapeutic Regimen for Cushing’s Disease

Transsphenoidal ACTH adenoma resection is the primary intervention, with 70%–80% gross total resection rates for microadenomas. Short-term glucocorticoid replacement is required for postoperative adrenocortical insufficiency. Bilateral adrenalectomy is performed for untreatable pituitary lesions, requiring lifelong hormonal replacement.

Adrenocortical enzyme inhibitors (metyrapone, ketoconazole) are used for medical control, while radiotherapy is applied for residual or recurrent tumors with limited efficacy.

5.4 Management of Non-Functional Pituitary Tumors

Surgical intervention is indicated for tumors causing visual impairment, intractable headache, or progressive hypopituitarism, or lesions growing > 2 mm during follow-up. Regular postoperative MRI and hormonal monitoring are mandatory, with individualized hormone replacement therapy for patients with persistent pituitary insufficiency.

6. Perioperative Nursing and Holistic Management

6.1 Medication Nursing

Dopamine agonists are administered postprandially with initial bed rest to prevent orthostatic hypotension, with monthly PRL monitoring for dose adjustment. Somatostatin analog injections require regular site rotation to avoid local irritation, with abdominal ultrasound surveillance for cholelithiasis prevention.

6.2 Postoperative Core Nursing

After transsphenoidal surgery, the head of the bed is elevated by 30° to reduce CSF leak risk, with strict avoidance of forced coughing and nasal blowing. Nasal packing is removed within 24–48 hours, with close observation for clear rhinorrhea suggestive of CSF leakage.

Perioperative glucocorticoid and thyroid hormone replacement is standardized to prevent adrenal crisis and maintain metabolic stability, with regular dose titration based on functional tests.

6.3 Dietary, Exercise and Psychological Intervention

High-protein, high-fiber diets are recommended for postoperative recovery, with low-sodium, high-potassium diets for Cushing’s disease patients to correct electrolyte disorders. Early bed rest is followed by gradual moderate aerobic exercise, with strenuous resistance exercise prohibited for acromegalic patients.

Targeted psychological counseling and reproductive health guidance are provided for patients with sexual dysfunction and infertility to alleviate anxiety and improve quality of life.

7. Long-Term Follow-Up and Prognosis

7.1 Standard Follow-Up Protocol

Serial hormonal monitoring and contrast-enhanced pituitary MRI are performed regularly postoperatively. Stable prolactinoma patients are monitored every 3–6 months, while GH and ACTH tumor patients require quarterly biochemical tests. Annual imaging and bone density surveillance are essential for long-term complication prevention.

7.2 Prognostic Stratification

Medication-responsive prolactinomas have an excellent prognosis with a 5%–10% postoperative recurrence rate and normal life expectancy. Fully resected GH tumors achieve a 5-year survival rate over 90%, while uncontrolled cases have a 10–15 year shortened lifespan due to cardiovascular complications. Cushing’s disease patients with surgical remission have a 5-year survival rate of 80%–85%.

Non-functional tumors with total resection have a 70%–80% 5-year progression-free survival rate, while subtotally resected lesions require lifelong surveillance for progressive compression and hormonal deficiency.

7.3 Complication Prevention

Long-term hormonal replacement patients carry emergency medical cards for stress dose adjustment. Regular cardiovascular assessment and anti-osteoporosis therapy are mandatory for high-risk populations to reduce systemic complication risks.

8. Frequently Asked Questions

Q1: Do all pituitary tumors cause endocrine disorders?

Approximately 60%–70% of pituitary tumors induce endocrine abnormalities. Functional tumors cause hormone hypersecretion syndromes, while non-functional tumors trigger hormonal deficiency via mass compression and parenchymal atrophy.

Q2: What are the typical endocrine symptoms of pituitary tumors?

Female manifestations include menstrual irregularities, amenorrhea, galactorrhea, infertility and hirsutism. Male patients mainly present with decreased libido, erectile dysfunction, infertility and faded secondary sexual characteristics. Special subtypes cause distinctive syndromes: Cushing’s disease presents central obesity and hypertension; GH tumors induce acromegaly or gigantism combined with metabolic disorders such as diabetes and hypothyroidism.

Q3: How are pituitary tumor-related endocrine disorders treated?

Treatment is individualized by tumor subtype. Prolactinomas prioritize dopamine agonist medication; GH tumors and Cushing’s disease prioritize transsphenoidal microsurgery. Radiotherapy serves as an adjuvant for residual, recurrent or medically intractable tumors.

Q4: When is surgical intervention required?

Surgery is indicated for drug-resistant functional tumors, giant adenomas with visual compression, progressively enlarging non-functional tumors, and cases with severe irreversible endocrine dysfunction. Minimally invasive transsphenoidal surgery is the mainstream procedure with high safety and controllable complications.